This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Humana's (HUM) Q4 Earnings Beat on Healthcare Services?
by Zacks Equity Research
Humana's (HUM) fourth-quarter results are likely to reflect surging Healthcare Services profits on strong pharmacy business.
What Makes Haemonetics (HAE) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Haemonetics (HAE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com featured highlights include Clarivate, Expedia Group and Haemonetics
by Zacks Equity Research
Clarivate, Expedia Group and Haemonetics are part of the Zacks Screen of the Week article.
HCA Healthcare (HCA) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased equivalent admissions and outpatient surgery cases.
Time To Pick These 3 Top Relative Price Strength Stocks
by Nilanjan Choudhury
Clarivate Plc (CLVT), Expedia Group (EXPE) and Haemonetics Corporation (HAE) are three stocks with explosive relative price strength.
Elevance Health (ELV) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums, Commercial & Specialty Business' sales and total expenses.
Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Haemonetics (HAE) Q2 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Under the Hospital segment, despite continued macroeconomic, Haemonetics (HAE) meaningfully grows revenues and market share.
Company News for Nov 8, 2022
by Zacks Equity Research
Companies In The News Are: HAE, AMG, NI, PLTR.
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 18.57% and 8.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Haemonetics (HAE) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and contract wins enjoyed by its Medicaid business, partly offset by escalating operating expenses.
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Haemonetics (HAE) have performed compared to their sector so far this year.
Haemonetics (HAE) Hospital Arm Aids, Macro Issues Persist
by Zacks Equity Research
Robust performance of Haemonetics' (HAE) Hospital business, on continued strength in the Hemostasis Management product line, instills optimism.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics (HAE) to Offer Two VASCADE Devices in the EU
by Zacks Equity Research
Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.
Haemonetics (HAE) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Haemonetics (HAE) Stock Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) better-than-expected results and strong Plasma sales.
Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail
by Zacks Equity Research
Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business
by Zacks Equity Research
According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.
Lantheus Holdings, Inc. (LNTH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Lantheus Holdings (LNTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.